These guides are AI-generated educational summaries — not legal or medical advice.
C&P Exam Prep: Autoimmune Diseases (Lupus / Rheumatoid Arthritis / Gout)
DBQ Overview
Interview + Physical- Form Name
- Systemic_Lupus_Erythematosus_and_Other_Autoimmune_Diseases
- Form Code
- Systemic_Lupus_Erythematosus_and_Other_Autoimmune_Diseases
- Page Count
- 9
- Examiner Type
- Rheumatologist or Physician
- Estimated Duration
- 30-45 minutes
- Exam Format
- Interview + Physical
What to Expect During Your Exam
Exam Overview
To document the current severity, systemic manifestations, and functional impact of your diagnosed autoimmune condition (SLE, Discoid Lupus, Rheumatoid Arthritis, or related autoimmune disease) so the VA rater can assign an accurate disability rating under 38 CFR 4.88b (DC 6350), 4.118 (DC 7809), or 4.71a (DC 5002/5009).
What the examiner evaluates:
- Specific autoimmune diagnosis (SLE, Discoid Lupus, RA, Sj-gren's, Scleroderma, etc.) and date of diagnosis
- Frequency and severity of flare-ups and exacerbations
- Cutaneous manifestations (malar rash, discoid lesions, photosensitivity, alopecia, oral ulcers)
- Musculoskeletal involvement (joint swelling, tenderness, ROM limitation, arthritis)
- Renal involvement (proteinuria, hematuria, glomerulonephritis, elevated creatinine, reduced eGFR)
- Cardiac involvement (pericarditis, myocarditis, Libman-Sacks endocarditis, valvular disease)
- Pulmonary involvement (pleuritis, pulmonary emboli, pulmonary hypertension, shrinking lung syndrome)
- Hematologic abnormalities (anemia, leukopenia/lymphopenia, thrombocytopenia)
- Neurological manifestations (seizures, psychosis, cognitive changes, neuropathy)
- Serologic markers (ANA, anti-dsDNA, anti-Sm, anti-Ro, complement levels C3/C4, antiphospholipid antibodies)
- Current medications including oral corticosteroids, immunosuppressives, and biologics
- Impact on occupational and daily functioning
- Constitutional symptoms: fatigue, fever, weight loss
- Recent laboratory and imaging results
The exam may occur at a VA medical center, a contract examination facility (QTC, LHI/Optum, VES), or via telehealth. Bring all relevant medical records, lab results, and a list of current medications. The examiner will review your claims file and conduct a physical examination. In many states you have the right to record the exam - check your state law and notify the examiner at the start.
Typical duration: 30-45 minutes
ANA (Antinuclear Antibody) Titer
Presence and magnitude of antinuclear antibodies, a hallmark serologic finding in SLE and many other autoimmune conditions.
What to expect:
The examiner will review prior lab results and may note titer level and pattern (homogeneous, speckled, etc.). A titer of -1:80 is generally considered positive.
Key thresholds:
- -1:80 positive — Supports autoimmune diagnosis for service connection and severity rating under DC 6350
- High titer with positive anti-dsDNA — Stronger evidence of active SLE; supports higher severity rating
Tips:
- Bring copies of all ANA test results, including dates and titers, to the exam.
- If your ANA fluctuates, bring multiple results to show the pattern over time.
- Note whether testing was done during a flare vs. remission period.
Pain considerations: ANA testing is a blood draw; not directly painful, but active disease causing joint pain or fatigue may make travel to labs difficult - communicate this functional burden.
Anti-dsDNA (Anti-Double-Stranded DNA) Antibody
Highly specific marker for SLE; levels often correlate with disease activity and renal flares.
What to expect:
The examiner will review prior results. Elevated levels are associated with active lupus nephritis and systemic flares.
Key thresholds:
- Positive / elevated — Supports diagnosis of active SLE; relevant to severity rating under DC 6350
- Rising levels during flare — Documents disease activity; important for establishing flare frequency
Tips:
- Bring all anti-dsDNA lab results with dates.
- If levels rose during a hospitalization or significant flare, bring those records.
- Correlate lab dates with symptom diaries if available.
Pain considerations: Communicate any functional limitations that prevented timely lab follow-up during flares.
Complement Levels (C3 and C4)
Low complement levels indicate complement consumption from immune complex deposition, a sign of active SLE, particularly lupus nephritis.
What to expect:
Examiner will review C3 and C4 values. Low levels during flares are clinically significant.
Key thresholds:
- C3 < 90 mg/dL or C4 < 16 mg/dL (low) — Indicates active disease; supports higher severity rating
Tips:
- Bring a log of C3/C4 results over time - trends matter as much as single values.
- Note whether low levels corresponded with hospitalizations or severe flares.
Pain considerations: Document how fatigue from active disease affected your ability to attend lab appointments.
Complete Blood Count (CBC) - Hemoglobin, Hematocrit, WBC, RBC, Platelet Count
Evaluates hematologic manifestations of autoimmune disease including hemolytic anemia (low Hgb/Hct), leukopenia/lymphopenia, and thrombocytopenia.
What to expect:
The examiner will document any abnormal CBC values. Lymphopenia (<1,500 cells/-L) and thrombocytopenia are specific criteria in the SLE DBQ.
Key thresholds:
- Hemoglobin < 11 g/dL (anemia) — Documents hematologic manifestation; may support higher overall rating
- WBC < 4,000 cells/-L or lymphocytes < 1,500/-L — Fulfills SLE diagnostic criterion; supports active disease documentation
- Platelets < 100,000/-L — Autoimmune thrombocytopenia; can be life-threatening; supports severity
Tips:
- Bring all CBC results, especially those taken during flares.
- If you have had transfusions or hospitalizations for hematologic crises, bring those records.
- Document any infections or bleeding episodes attributable to low counts.
Pain considerations: Fatigue from anemia significantly impacts daily function - describe this as a separate disabling symptom.
Renal Function Panel - BUN, Creatinine, eGFR
Assesses kidney function and damage from lupus nephritis or other autoimmune renal involvement.
What to expect:
Examiner will document current and historical values. Elevated creatinine, reduced eGFR, and abnormal BUN indicate renal impairment.
Key thresholds:
- eGFR < 60 mL/min (Stage 3 CKD) — Significant renal impairment; may warrant separate renal rating under DC 7101 or higher combined rating
- Creatinine > 1.5 mg/dL — Elevated creatinine documents active nephritis or chronic kidney damage
Tips:
- Bring all renal function lab results, especially from nephrology visits.
- If you have had a kidney biopsy confirming lupus nephritis, bring pathology reports.
- Note any dietary restrictions or medications prescribed for kidney disease.
Pain considerations: Renal impairment causes fatigue, edema, and hypertension - each of these functional impacts should be separately described.
Urinalysis (with Microscopy)
Detects proteinuria, hematuria, hyaline casts, granular casts, and RBC casts - key indicators of lupus nephritis activity.
What to expect:
Examiner will review urinalysis results. The DBQ specifically tracks protein, blood, glucose, hyaline casts, granular casts, and microscopic findings.
Key thresholds:
- Protein - 500 mg/24h or 3+ on dipstick — Significant proteinuria; supports lupus nephritis diagnosis and higher severity
- RBC casts present — Indicates active glomerulonephritis; important for renal rating
Tips:
- Bring the most recent urinalysis result with date.
- If you have had 24-hour urine protein collections, bring those reports.
- Note any visible blood in urine or foamy urine as functional symptoms.
Pain considerations: Edema from nephrotic syndrome causes pain, difficulty walking, and limits daily activities - describe these impacts specifically.
ESR (Erythrocyte Sedimentation Rate) and CRP (C-Reactive Protein)
Non-specific markers of systemic inflammation. Elevated values indicate active disease; used to document flare activity.
What to expect:
Examiner will note values relative to normal ranges. ESR is commonly elevated in SLE and RA.
Key thresholds:
- ESR > 50 mm/hr — Indicates significant active inflammation; supports active disease documentation
- CRP elevated during flare — Documents inflammatory activity; supports flare frequency claims
Tips:
- Bring ESR and CRP results from multiple time points, including during documented flares.
- ESR elevation during a documented work absence or hospitalization strengthens functional impact claims.
Pain considerations: High ESR and CRP correlate with pain and fatigue severity - describe how inflammation physically felt during those periods.
Joint Range of Motion (ROM) Assessment (for RA / Autoimmune Arthritis)
Active and passive ROM of affected joints; evaluated under DeLuca factors for pain, fatigue, weakness, incoordination, and flare-up effects per 38 CFR 4.40 and 4.45.
What to expect:
Examiner will measure ROM of affected joints using a goniometer. Both active and passive motion will be tested. Weight-bearing and non-weight-bearing tests may be performed for lower extremity joints per Correia requirements.
Key thresholds:
- Ankylosis of major joint — Up to 60% for major joint ankylosis under DC 5003/5002
- Limited motion below normal values — Rated by analogy under applicable joint DC; each affected joint rated separately
Tips:
- Test should reflect your WORST DAY function, not your best day at the exam.
- If motion is painful, state so clearly during the exam - pain on motion is separately ratable.
- Report fatigue after repeated use (DeLuca factors) - if your joints worsen after 5 repetitions, say so.
- Describe morning stiffness duration - this is relevant to RA severity.
- Bring photos or videos of flare-affected joints if possible.
Pain considerations: Pain with motion, after motion, and at rest should all be separately described. Fatigue after repetitive use is a DeLuca factor that can support a higher rating even when resting ROM appears adequate.
Rating Criteria Breakdown
| Rating % | Criteria | Key Symptoms |
|---|---|---|
| 100% | SLE (DC 6350): Persistent signs and symptoms at the 60% level AND requires regular hospital, residential, or nursing home-level care. OR for Discoid Lupus (DC 7809) / skin ratings: More than 40% of the entire body or more than 40% of exposed areas affected, OR constant or near-constant systemic therapy (immunosuppressives, retinoids, biologics, or oral corticosteroids) required over the past 12 months. |
CFR: 38 CFR 4.88b DC 6350: Persistent signs and symptoms of active disease or complications requiring regular professional supervision. 38 CFR 4.118 DC 7809 via General Rating Formula for Skin: Constant or near-constant systemic therapy required. |
| 60% | SLE (DC 6350): Exacerbations occurring 3 or more times per year, OR; requiring prolonged (6 weeks or more) treatment with systemic corticosteroids or other immunosuppressives, OR; resulting in hospitalization OR; with pronounced involvement of multiple major organs (kidneys, heart, lungs, CNS). For skin (DC 7809): 20-40% of the entire body or 20-40% of exposed areas affected, OR systemic therapy required for a total of 6 weeks or more but not constantly during the past 12 months. |
CFR: 38 CFR 4.88b DC 6350: Exacerbations 3+ per year or prolonged treatment requiring systemic corticosteroids. 38 CFR 4.118 DC 7809: 20-40% BSA or systemic therapy 6+ weeks in 12 months. |
| 40% | SLE (DC 6350): Exacerbations 2 times per year or requiring prolonged corticosteroid/immunosuppressive therapy. For skin (DC 7809): At least 5% but less than 20% of the entire body or at least 5% but less than 20% of exposed areas affected, OR intermittent systemic therapy required for at least 6 weeks in the past 12 months. RA (DC 5002): With constitutional manifestations, significant joint deformity, ankylosis, or other disability. |
CFR: 38 CFR 4.88b DC 6350: Exacerbations 2x/year or requiring prolonged treatment. 38 CFR 4.118 DC 7809: 5-20% BSA or systemic therapy -6 weeks. 38 CFR 4.71a DC 5002: With constitutional manifestations. |
| 10% | SLE (DC 6350): Exacerbations once a year. Skin (DC 7809): Less than 5% of the entire body or less than 5% of exposed areas affected AND no more than topical therapy required during the past 12 months. RA: Occasional exacerbations, use of NSAIDs or disease-modifying agents, minimal functional impairment. |
CFR: 38 CFR 4.88b DC 6350: One exacerbation per year. 38 CFR 4.118 DC 7809: Less than 5% BSA, topical therapy only. |
| 0% | SLE or autoimmune condition that is service-connected but currently in complete remission with no active symptoms, no medications required, and no functional impairment. Condition is noted and rated non-compensably to preserve the service connection in the event of future worsening. |
CFR: 38 CFR 4.88b DC 6350 and 38 CFR 4.118 DC 7809: Condition in complete remission. Service connection preserved at 0%. |
100% SLE (DC 6350): Persistent signs and symptoms at the 60% leve ...
SLE (DC 6350): Persistent signs and symptoms at the 60% level AND requires regular hospital, residential, or nursing home-level care. OR for Discoid Lupus (DC 7809) / skin ratings: More than 40% of the entire body or more than 40% of exposed areas affected, OR constant or near-constant systemic therapy (immunosuppressives, retinoids, biologics, or oral corticosteroids) required over the past 12 months.
Key Symptoms
- Persistent active SLE despite maximum treatment
- Requires ongoing hospitalization or nursing-level supervision
- Severe multi-organ involvement (renal failure, CNS lupus, cardiac involvement)
- Inability to perform activities of daily living
- More than 40% body surface area involved with constant systemic therapy
CFR: 38 CFR 4.88b DC 6350: Persistent signs and symptoms of active disease or complications requiring regular professional supervision. 38 CFR 4.118 DC 7809 via General Rating Formula for Skin: Constant or near-constant systemic therapy required.
60% SLE (DC 6350): Exacerbations occurring 3 or more times per y ...
SLE (DC 6350): Exacerbations occurring 3 or more times per year, OR; requiring prolonged (6 weeks or more) treatment with systemic corticosteroids or other immunosuppressives, OR; resulting in hospitalization OR; with pronounced involvement of multiple major organs (kidneys, heart, lungs, CNS). For skin (DC 7809): 20-40% of the entire body or 20-40% of exposed areas affected, OR systemic therapy required for a total of 6 weeks or more but not constantly during the past 12 months.
Key Symptoms
- Frequent flares (3+ per year)
- Prolonged systemic corticosteroid or immunosuppressive courses (6+ weeks)
- Hospitalization for flare management
- Multi-organ involvement: renal, cardiac, pulmonary, neurological
- Significant anemia, leukopenia, or thrombocytopenia
- 20-40% body surface area skin involvement
CFR: 38 CFR 4.88b DC 6350: Exacerbations 3+ per year or prolonged treatment requiring systemic corticosteroids. 38 CFR 4.118 DC 7809: 20-40% BSA or systemic therapy 6+ weeks in 12 months.
40% SLE (DC 6350): Exacerbations 2 times per year or requiring p ...
SLE (DC 6350): Exacerbations 2 times per year or requiring prolonged corticosteroid/immunosuppressive therapy. For skin (DC 7809): At least 5% but less than 20% of the entire body or at least 5% but less than 20% of exposed areas affected, OR intermittent systemic therapy required for at least 6 weeks in the past 12 months. RA (DC 5002): With constitutional manifestations, significant joint deformity, ankylosis, or other disability.
Key Symptoms
- Exacerbations 2 times per year
- Requires intermittent systemic corticosteroids or immunosuppressives
- Constitutional symptoms: fatigue, fever, weight loss
- Moderate joint involvement with functional limitation
- 5-20% body surface area skin involvement
- Positive serologies with active symptoms
CFR: 38 CFR 4.88b DC 6350: Exacerbations 2x/year or requiring prolonged treatment. 38 CFR 4.118 DC 7809: 5-20% BSA or systemic therapy -6 weeks. 38 CFR 4.71a DC 5002: With constitutional manifestations.
10% SLE (DC 6350): Exacerbations once a year. Skin (DC 7809): Le ...
SLE (DC 6350): Exacerbations once a year. Skin (DC 7809): Less than 5% of the entire body or less than 5% of exposed areas affected AND no more than topical therapy required during the past 12 months. RA: Occasional exacerbations, use of NSAIDs or disease-modifying agents, minimal functional impairment.
Key Symptoms
- Occasional exacerbations (once per year or less)
- Managed primarily with topical therapy or NSAIDs
- Less than 5% body surface area skin involvement
- Mild joint involvement without significant limitation
- Stable laboratory markers
CFR: 38 CFR 4.88b DC 6350: One exacerbation per year. 38 CFR 4.118 DC 7809: Less than 5% BSA, topical therapy only.
0% SLE or autoimmune condition that is service-connected but cu ...
SLE or autoimmune condition that is service-connected but currently in complete remission with no active symptoms, no medications required, and no functional impairment. Condition is noted and rated non-compensably to preserve the service connection in the event of future worsening.
Key Symptoms
- Complete remission - no active symptoms
- No medications currently required
- Normal laboratory values
- No functional impairment
CFR: 38 CFR 4.88b DC 6350 and 38 CFR 4.118 DC 7809: Condition in complete remission. Service connection preserved at 0%.
How to Describe Your Symptoms
Flare-Up Frequency and Severity
How to describe:
Describe exactly how many flares you have had in the past 12 months, how long each lasted, what triggered them, what symptoms occurred, and what medical intervention was required (ER visits, hospitalizations, prednisone bursts, increased immunosuppressive dosing). Use specific dates if possible.
Worst-day example:
“During my worst flare in [month/year], I was bedridden for 14 days with joint pain so severe I could not dress myself, a butterfly rash covering my face and neck, extreme fatigue, a fever of 101.5-F, and my rheumatologist increased my prednisone to 40 mg daily for 3 weeks. I missed 10 consecutive days of work.”
What the examiner listens for:
The examiner needs to document flare frequency (1x/year = 10%, 2x = 40%, 3x+ = 60%) and whether flares require systemic treatment. Vague answers about 'getting worse sometimes' will not satisfy DBQ requirements.
Understatements to avoid:
Do not say 'I manage okay' or 'I push through it.' State clearly how each flare disabled you and what medical care was required. Do not minimize because you are having a good day at the exam.
Fatigue and Constitutional Symptoms
How to describe:
Describe your fatigue as a separate, disabling symptom distinct from joint pain. Quantify it: rate it on a 0-10 scale on your worst days, describe how many hours per day you can be functional, and identify activities you can no longer perform or complete. Also describe any fevers, unexplained weight loss, and night sweats.
Worst-day example:
“On my worst days - which occur at least [X] times per month - my fatigue is a 9/10. I cannot get out of bed before noon, I cannot cook my own meals, and I require assistance with basic hygiene. Even on moderate days, I am exhausted after 2-3 hours of light activity and must rest for several hours before resuming.”
What the examiner listens for:
Fatigue is a critical functional symptom in autoimmune conditions. The examiner needs concrete examples of how fatigue limits occupational and daily activities. This supports both the overall rating and potential TDIU claims.
Understatements to avoid:
Do not say 'I am tired' without quantifying the impact. Do not say 'I have good days and bad days' without describing the full spectrum - the VA rates based on the average impact including your worst days, not just your best days.
Joint Pain, Swelling, and Stiffness (Musculoskeletal)
How to describe:
Identify every joint affected by name (bilateral wrists, MCPs, PIPs, knees, ankles, etc.). Describe pain at rest, pain with motion, swelling frequency, and morning stiffness duration. Apply DeLuca factors: describe pain, fatigue, weakness, incoordination, and how symptoms worsen with repetitive use or flares.
Worst-day example:
“During flares, the pain in my bilateral wrists and finger joints is 8/10 at rest and 10/10 with any gripping activity. Morning stiffness lasts 2-3 hours. I cannot open jars, type for more than 10 minutes, or turn a steering wheel. After even brief activity, my joints swell visibly and the pain increases significantly for the next 24 hours.”
What the examiner listens for:
The examiner will document affected joints for the DBQ's joint section. For RA rated under DC 5002, the number of joints affected, functional limitation, and whether constitutional manifestations are present determines the rating level. DeLuca factors - especially pain with motion and after repetitive use - directly affect the rating.
Understatements to avoid:
Do not perform at your maximum ability during ROM testing if it causes pain. Tell the examiner 'this hurts' during each motion. Do not omit joints that are intermittently affected - all joints affected during flares should be reported.
Skin Manifestations (Rash, Alopecia, Oral Ulcers)
How to describe:
Describe the type, location, frequency, and extent of skin involvement. For malar rash: where it appears, how long it lasts, whether it is photosensitive, and what percentage of your face/exposed skin it covers. For alopecia: how much hair you lose, whether it scars, and the psychological impact. For oral ulcers: frequency, pain level, and impact on eating.
Worst-day example:
“During active flares my butterfly rash covers both cheeks, the bridge of my nose, and spreads to my neck - roughly 15-20% of my exposed facial area. It burns and itches, causes visible disfigurement, and I avoid sun exposure entirely because UV light reliably triggers a full systemic flare within 48 hours. I have had scarring hair loss resulting in visible bald patches approximately [size] that do not regrow.”
What the examiner listens for:
The examiner will document the specific skin areas affected on the DBQ (cheeks, nose, scalp, hands, feet, lips/mouth, chin, ears, etc.) and estimate body surface area involvement. The percentage of BSA involved is the primary driver of skin ratings under DC 7809. Mention all areas affected - the examiner needs to check every applicable box.
Understatements to avoid:
Do not say 'I get a rash sometimes.' Specify location, extent, frequency, and what aggravates it. Do not omit oral ulcers or scalp involvement - these are separately noted on the DBQ and contribute to the overall picture of active disease.
Organ System Involvement (Renal, Cardiac, Pulmonary)
How to describe:
For each organ system affected, describe when it was diagnosed, what symptoms you experience, what treatments were prescribed, and how it limits your daily function. Renal: swelling, foamy urine, elevated BP, dietary restrictions. Cardiac: chest pain, palpitations, shortness of breath at rest. Pulmonary: shortness of breath with exertion, pleuritic chest pain, reduced exercise tolerance.
Worst-day example:
“Due to lupus nephritis, I have persistent leg swelling to mid-calf requiring compression stockings and diuretics. My blood pressure requires two medications to control. I can walk approximately one block before becoming short of breath. I cannot climb stairs without stopping to rest. On my worst days, the swelling extends to my thighs and I cannot wear shoes.”
What the examiner listens for:
Each organ system involvement is separately documented on the DBQ and can lead to additional separate ratings (e.g., renal under DC 7101, cardiac under appropriate DC, pulmonary under DC 6600-series). Be specific and thorough - the examiner can only check boxes for manifestations that are reported and documented.
Understatements to avoid:
Do not say 'my kidneys are a little affected.' Give specific numbers when available (creatinine level, 24-hour protein, eGFR). Do not omit symptoms because 'they are being treated' - the treatment requirement itself is evidence of severity.
Medication Burden and Side Effects
How to describe:
List every medication you take for your autoimmune condition, the dose, duration, and reason. Specifically identify oral corticosteroids (prednisone), immunosuppressives (methotrexate, mycophenolate, azathioprine, cyclophosphamide), biologics (Benlysta/belimumab, rituximab), hydroxychloroquine, and any topical agents. Describe side effects that themselves are disabling.
Worst-day example:
“I have been on prednisone ranging from 5 to 40 mg daily for the past 3 years due to recurrent flares. Side effects include weight gain of 35 lbs, avascular necrosis of my right hip requiring monitoring, glucose intolerance, insomnia, and mood disturbances. I also take mycophenolate 1,500 mg twice daily which causes chronic nausea and diarrhea limiting my ability to leave my home reliably.”
What the examiner listens for:
The DBQ has specific checkboxes for oral corticosteroids, immunosuppressives/retinoids, topical corticosteroids, and other immunosuppressive medications - including duration. Prolonged systemic therapy is a direct rating criterion at the 60-100% level. The examiner needs the medication list and duration to complete these fields accurately.
Understatements to avoid:
Do not forget to list all autoimmune medications including OTC NSAIDs taken for symptom management. Do not understate duration - if you have been on corticosteroids intermittently for years, the total cumulative duration matters. Side effects of medications that themselves cause disability may support secondary service connection claims.
Impact on Work and Daily Activities
How to describe:
Describe in concrete terms how your autoimmune condition prevents or limits work attendance, job performance, and activities of daily living. Use specific examples: missed work days per month, tasks you can no longer perform, accommodations required, inability to sustain full-time employment.
Worst-day example:
“In the past 12 months I have missed approximately [X] days of work due to flares and medical appointments. My employer has placed me on intermittent FMLA. I cannot perform my previous job duties of [specific tasks] due to joint pain, fatigue, and cognitive fog from my condition and medications. On bad weeks, I cannot drive, prepare meals, or perform personal hygiene without assistance.”
What the examiner listens for:
The DBQ has a specific field asking the examiner to describe the impact of the autoimmune disease on occupation and daily activities. This section directly informs TDIU eligibility and the overall rating narrative. Concrete, specific functional limitations are far more persuasive than general statements.
Understatements to avoid:
Do not say 'I try to stay active.' Do not say you are 'managing' if you are actually struggling. The VA rates based on how your condition actually functions - on your average and worst days - not how optimistically you present yourself on a good exam day.
Common Mistakes to Avoid
Reporting only current (exam-day) symptoms rather than typical and worst-day symptoms
VA ratings are based on the average disability picture including flares and worst-day presentations. Veterans frequently present well on exam day and describe only mild current symptoms, resulting in a rating far below their actual disability level.
Instead: Per M21-1 guidance, explicitly tell the examiner: 'Today is not a typical day for me. My worst days look like [description].' Describe your average day, your worst days, and how often worst days occur. Bring a symptom diary if available.
Impact: Can result in 10-40% rating when 60-100% is warranted
Failing to mention all affected organ systems
The SLE DBQ has separate sections for renal, cardiac, pulmonary, hematologic, neurological, and cutaneous manifestations. Each system must be affirmatively reported - the examiner will not ask about every system if you do not bring it up.
Instead: Before the exam, review the list of organ systems covered by SLE and prepare to report involvement in each affected system. Bring supporting lab results, imaging reports, and specialist notes for each organ system.
Impact: Missing organ system documentation can prevent 60-100% ratings and block secondary condition ratings
Not quantifying flare frequency with specific numbers
The rating criteria under DC 6350 are directly tied to flare frequency: 1x/year = 10%, 2x/year = 40%, 3x+/year = 60%. If you say 'I have flares sometimes' the examiner cannot accurately complete the DBQ flare section.
Instead: Count your flares for the past 12 months before the exam. Write them down with approximate dates, duration, symptoms, and treatment required. Be specific: 'I have had 4 flares in the past 12 months, each lasting approximately 2-3 weeks and requiring prednisone.'
Impact: Difference between 10%, 40%, and 60% rating
Not disclosing all medications and their duration
Prolonged systemic corticosteroid or immunosuppressive therapy (6+ weeks) is an independent rating criterion at 60% and above. If you do not report all medications and how long you have used them, this criterion may be missed.
Instead: Bring a complete, written medication list including drug name, dose, start date, any interruptions, and current status. Include all immunosuppressives, biologics, hydroxychloroquine, NSAIDs, and corticosteroids.
Impact: Can prevent 60-100% rating based on treatment burden alone
Performing at maximum ability during physical examination
Veterans instinctively try to show what they can do. If you perform a full ROM without reporting pain, the examiner records full painless ROM, which drives a low musculoskeletal rating. DeLuca factors require active reporting of pain during and after motion.
Instead: During every movement that causes any degree of pain, say 'that hurts' and rate the pain aloud (e.g., '6 out of 10'). After repeated motions, report if fatigue or increased pain develops. Report how your function would differ during a flare.
Impact: Can result in 0-10% musculoskeletal rating when 20-40%+ is warranted under DeLuca
Failing to connect cognitive symptoms ('lupus fog') to the autoimmune condition
Neuropsychiatric SLE (NPSLE) including cognitive impairment, memory problems, and difficulty concentrating can support separate or higher ratings. If not reported and documented, these symptoms are not captured.
Instead: Describe cognitive symptoms specifically: 'I have significant difficulty with short-term memory and concentration. I forget appointments, cannot follow multi-step instructions, and have lost several job responsibilities due to cognitive errors.' Ask if neuropsychological testing has been done and bring results.
Impact: Missing neuropsychiatric documentation can prevent additional ratings and TDIU support
Not mentioning how photosensitivity triggers systemic flares
Photosensitivity in SLE is not just a skin issue - sun exposure reliably triggers full systemic flares for many veterans. This connection between environmental exposure and systemic disease activity is important for establishing the severity and frequency of flares.
Instead: Describe photosensitivity explicitly: 'Even brief sun exposure (15-20 minutes) triggers a systemic flare within 24-48 hours, requiring prednisone and days off work. I must avoid all sun exposure year-round, which limits my activities and employment options significantly.'
Impact: Supports higher flare frequency documentation; relevant to 40-60% level
Not bringing supporting documentation to the exam
The examiner is only obligated to review what is in your claims file. Records from private rheumatologists, nephrology, cardiology, and outside labs may not be in your VA file. Without these records, important manifestations and lab values may not be documented.
Instead: Bring copies of: all specialist visit notes (rheumatology, nephrology, cardiology), lab results (ANA, anti-dsDNA, CBC, CMP, urinalysis, complement levels), imaging reports, biopsy pathology reports, and any hospitalizations related to your autoimmune condition.
Impact: Affects all rating levels - documentation gaps most commonly prevent 60-100% ratings
Prep Checklist
Before Your Exam
Day Of
During the Exam
After the Exam
Your Rights During a C&P Exam
- You have the right to request a copy of your completed C&P examination DBQ after the exam through VA.gov, MyHealtheVet, or a FOIA request.
- You have the right to record your C&P examination in most states - check your state's consent laws (one-party vs. two-party consent) and notify the examiner at the start of the exam.
- You have the right to bring a VSO representative, accredited claims agent, or accredited attorney to assist you in preparing for and attending the exam.
- You have the right to submit additional evidence after the C&P exam and before the rating decision is issued, including buddy statements, private nexus letters, and additional medical records.
- You have the right to request a new C&P examination if you believe the original examination was inadequate, failed to address all claimed conditions, or contained factual errors - file a Notice of Disagreement (NOD) or supplemental claim with supporting rationale.
- You have the right to a fully favorable rating under the benefit-of-the-doubt standard (38 U.S.C. - 5107(b)) - when the evidence is approximately equal for and against your claim, the VA must rule in your favor.
- You have the right to appeal any rating decision through the Supplemental Claim, Higher-Level Review, or Board of Veterans' Appeals (BVA) lanes under the AMA appeals process.
- You have the right to submit a private medical opinion or independent medical examination (IME) as evidence to rebut or supplement the VA examiner's findings.
- You have the right to request a higher-level review if you believe the rating decision contained clear and unmistakable error, without submitting new evidence.
- Under 38 CFR 3.159, the VA has a duty to assist you by obtaining relevant records, ordering examinations, and informing you of what evidence is needed - if they failed in this duty, you may raise this in an appeal.
- For SLE, you should confirm whether your condition may qualify as a presumptive service connection based on your service history, particularly if you served in specific locations or were exposed to specific hazards covered under PACT Act or other presumptive provisions.
Related Conditions
- Lupus Nephritis / Chronic Kidney Disease Renal involvement is a primary manifestation of SLE. Lupus nephritis can be separately rated under DC 7101 (hypertensive vascular disease) or renal disease DCs in addition to the overall SLE rating. Proteinuria, hematuria, elevated creatinine, and reduced eGFR documented in the SLE DBQ support this secondary rating.
- Pericarditis / Myocarditis (Cardiac Manifestations of SLE) Cardiac manifestations including pericardial effusion, myocarditis, Libman Sacks endocarditis, valvular involvement, and coronary artery vasculitis are documented on the SLE DBQ and may warrant separate cardiac ratings. These are commonly under claimed secondary conditions.
- Pulmonary Hypertension / Pleuritis Pulmonary manifestations of SLE including recurrent pleuritis, pulmonary emboli, pulmonary hypertension, and shrinking lung syndrome are documented on the DBQ and may support separate respiratory ratings under DC 6600 series.
- Anemia (Hemolytic Autoimmune Anemia) Hemolytic anemia secondary to SLE or RA is documented in the hematologic section of the SLE DBQ and may be separately rated under DC 7700 series blood dyscrasia codes as a secondary service connected condition.
- Antiphospholipid Syndrome / Thrombosis Antiphospholipid antibodies, recurrent arterial thrombosis, and recurrent venous thrombosis are specifically documented in the SLE DBQ. Antiphospholipid syndrome may be separately ratable and increases the severity of the overall autoimmune presentation.
- Sj-gren's Syndrome Sj gren's syndrome frequently co occurs with SLE and RA. It is listed as a separate diagnosable condition on the SLE DBQ. Dry eyes, dry mouth, and associated neuropathy may be separately ratable when secondary to or concurrent with SLE.
- Scleroderma Scleroderma (systemic sclerosis) is listed on the SLE DBQ as a co occurring autoimmune diagnosis. It may be rated separately under DC 7871 and is associated with significant Raynaud's phenomenon, esophageal dysmotility, and pulmonary fibrosis.
- Rheumatoid Arthritis RA is rated under DC 5002 (multi joint arthritis) or DC 5009 (other autoimmune arthropathy). It may co occur with SLE or be the primary autoimmune diagnosis. The SLE DBQ captures RA as a diagnosed condition and documents joint involvement. Additional joint specific ratings may be available.
- Major Depressive Disorder / Anxiety (Secondary to Chronic Illness) Depression and anxiety are well documented secondary conditions to chronic autoimmune diseases due to chronic pain, disfigurement, medication side effects, and disability. A separate mental health rating secondary to SLE/RA can be claimed with appropriate nexus documentation.
- Avascular Necrosis (Secondary to Corticosteroid Use) Long term corticosteroid use for autoimmune disease management is a leading cause of avascular necrosis (osteonecrosis), particularly of the femoral heads and humeral heads. This condition is separately ratable under DC 5250/5251/5252 and should be claimed as secondary to the autoimmune condition and its treatment.
- Osteoporosis / Vertebral Compression Fractures Prolonged corticosteroid use for autoimmune disease causes significant bone density loss and increased fracture risk. Osteoporosis and related fractures may be ratable as secondary to autoimmune disease and steroid treatment.
- Peripheral Neuropathy (Secondary to Autoimmune Disease) Autoimmune mediated peripheral neuropathy can occur in SLE, RA, and Sj gren's syndrome. Neuropathy may be separately ratable under DC 8100 series and should be evaluated with nerve conduction studies. Report any numbness, tingling, weakness, or burning in the extremities.
Get Personalized C&P Exam Preparation
Upload your medical records for AI-powered prep that maps YOUR symptoms to the exact DBQ fields your examiner will evaluate.
This C&P exam preparation guide is for educational purposes only and does not constitute legal, medical, or claims advice. Always consult with a qualified Veterans Service Organization (VSO) representative or VA-accredited attorney for guidance specific to your claim. Never exaggerate, minimize, or fabricate symptoms during a C&P examination.